The dream of detecting multiple cancers from a single blood draw, before symptoms arise, is inching from science fiction toward clinical reality. Multi-Cancer Early Detection (MCED) tests, which analyze biomarkers like circulating tumor DNA (ctDNA) in the blood, promise to revolutionize oncology by shifting diagnosis to earlier, more treatable stages. The potential impact is staggering: a recent study in The Lancet suggested that earlier detection could reduce late-stage cancer incidence by up to 39% for some tumor types. The financial markets have taken note, with the sector attracting billions in investment and strategic acquisitions.
This momentum was catalyzed in November 2025 by the blockbuster announcement that Abbott Laboratories would acquire Exact Sciences, a leader in cancer screening, for a reported $23 billion. This deal has thrown a spotlight on the entire MCED landscape, raising urgent questions about valuation, regulatory pathways, and the race for market dominance.
To navigate this complex and rapidly evolving field, the Drug and Device World sat down with Elena Meng, portfolio manager and research analyst covering global healthcare at Gabelli Funds. Meng, author of a detailed whitepaper on the MCED space, dissects the strategic rationale behind the Abbott-Exact deal, evaluates the fragile promise of pioneers like Grail and Guardant Health, and outlines the formidable commercial and regulatory hurdles that will determine whether MCED becomes a routine pillar of preventive care or a niche, cash-pay offering.
Abbott’s Bet and the Exact Sciences Story
The acquisition announcement on November 20 was notable for its scale and decisiveness: Abbott agreed to acquire Exact Sciences for $105 per share in an all-cash transaction, valuing the company at approximately $21bn equity value and roughly $23bn enterprise value. For Meng, however, the deal was not unexpected. “I wasn’t surprised,” Meng said, framing it as part of a broader strategy among large healthcare and life science players — including Abbott, Danaher, and Thermo Fisher — to acquire commercially proven diagnostic platforms with durable reimbursement and credible growth runways.
For Meng, the appeal of Exact Sciences begins with its foundation: Cologuard, a stool-based colorectal cancer screening test with broad coverage and demonstrated adoption. “Cologuard is a proven commercial engine,” she said. Exact reports more than 20 million Cologuard screenings have been completed since launch, giving the company a rare asset in diagnostics: a scaled product with real-world utilization, entrenched payer relationships, and consumer awareness.
That foundation matters because it supports reinvestment. The recent launch of Cologuard Plus — with improved performance and a higher reimbursement rate — strengthens the company’s growth outlook. “In my view, it supports a path to sustained high-teens revenue growth,” Meng noted, adding that revenue momentum is especially valuable for a company still transitioning toward sustained EPS profitability.
Exact Sciences’ Provable Prowess
At the same time, Meng emphasized that Exact’s trajectory also reflects the inherent volatility of the diagnostics sector. The stock sold off sharply in November 2024 amid concerns over Cologuard volume durability, and again in mid-2025 after the company’s internally developed blood-based CRC program failed to clear key performance benchmarks.
What shifted sentiment, in Meng’s view, was the company’s response: moving quickly to license a blood-based CRC test from Freenome. “That decision demonstrated strategic discipline,” she said. “They didn’t force a weaker internal program forward — they pivoted to an alternative they viewed as more competitive.” Meng added that the pivot reinforced her view that the shares were “materially mispriced at the time.”
More broadly, Meng argues Exact has demonstrated a rare capability in diagnostics: the ability to drive adoption at scale and secure durable payer coverage. “Commercial execution is often underestimated,” she said. “Abbott is effectively buying a platform with an established US reimbursement engine — and the ability to extend that playbook internationally.”
Meng acknowledged the acquisition multiple appears elevated. “At roughly seven to eight times sales, it screens as a premium multiple,” she said. “But the real value is the optionality.” Just weeks before the acquisition, Exact launched its first MCED test, priced at $689, and early conference feedback suggested a meaningful portion of consumers were willing to pay out-of-pocket. “It signals real demand and unmet need,” Meng said, while noting that durable market expansion will ultimately depend on regulatory clarity and the development of a viable reimbursement model.
The MCED Landscape
The market’s valuation of MCED companies reflects a clear hierarchy — one that can be framed around proof, platform, and promise, a framework Meng outlined.
At the infrastructure end sits Quest Diagnostics, which trades at roughly ~2.5x sales. As described in the Gabelli whitepaper, Quest’s core advantage is scale and logistics: a nationwide network reaching ~650,000 clinicians, supported by ~6,000 in-office phlebotomists, ~2,000 patient service centers, and a rapid courier system. Quest is already deeply embedded in the testing ecosystem and is positioned as a critical collection and processing backbone for emerging blood-based screening modalities, while also investing in internal innovation, including protein biomarker approaches in collaboration with MD Anderson. “Quest functions more like a distributor,” Meng said.
Exact Sciences (now under Abbott) and Guardant Health occupy the middle tier, where commercial execution and platform breadth begin to matter more. Guardant — anchored by its Shield blood-based CRC screening franchise, with optionality into broader oncology applications — has historically traded at a materially higher multiple, reflecting investor willingness to pay for platform potential. Meng described Guardant as “a more exciting name in terms of proven technology,” citing both its regulatory momentum in blood-based CRC screening and the breadth of its portfolio across screening (Shield), monitoring (Reveal for MRD), and profiling (Guardant360). “Their concept is really a platform,” she said — and she views that platform strategy as increasingly becoming the norm.
At the high end sits Grail, the pure-play MCED pioneer behind Galleri, which can detect signals across 50+ cancers. Meng identified Grail as the sector’s bellwether, in part because it is among the most advanced programs moving toward regulatory submission for a multi-cancer indication. That perceived first-mover advantage is reflected in a pro-forma valuation of ~27.5x sales — a premium that embeds aggressive expectations for clinical execution, regulatory success, and ultimately broad reimbursement. “At that multiple,” Meng noted, “the market is effectively underwriting near-perfect execution.”
The Pivotal Hurdle: FDA Approval and the Grail Litmus Test
Looking across the broader MCED landscape, Meng described Grail as the sector’s regulatory and commercial bellwether. “This is the inflection point everyone is watching,” she said, referring to Grail’s path toward FDA submission and the signal it would send to both payers and the broader diagnostics ecosystem.
“The data is promising, but it’s not yet conclusive,” Meng cautioned. Grail’s Pathfinder 2 study (NCT05155605) reported a positive predictive value (PPV) in the ~60–62% range — an important step forward, but not yet definitive at population scale. In her view, the technical progress is meaningful, but the bar remains high, particularly in low-prevalence screening populations where false positives can create significant downstream burden. “Even with very high specificity, at population scale the absolute number of false positives becomes non-trivial,” she said. “That has real workflow and cost implications for the healthcare system.” The Gabelli whitepaper echoes this point, identifying the need for reliable sensitivity and specificity in low-prevalence, asymptomatic populations as a top industry challenge.
Meng outlined three hurdles that MCED tests ultimately must clear to achieve durable adoption:
- Demonstrating outcome-level benefit: Regulators and payers will increasingly require evidence that earlier detection translates into improved survival or reduced morbidity — not merely the ability to detect cancer earlier.
- Managing false positives and follow-up pathways: Even at ~99% specificity, false positives at population scale can lead to costly diagnostic cascades and patient anxiety. Clear triage protocols and streamlined care pathways are essential.
- Earning physician trust and integrating into clinical workflow: Adoption requires seamless ordering and reporting within electronic health records (EHRs), and solutions that address primary care concerns around navigation, follow-up, and patient affordability.
A Grail FDA approval, Meng believes, would be catalytic — validating the regulatory pathway and likely lifting sentiment across the category. A rejection or delay, however, could have a material “domino effect” across the space. That said, she added, even an adverse outcome would not mark “the end of the market,” but rather force a more disciplined reset in expectations and valuation.
The Reimbursement Quandary
Even with regulatory progress, Meng argues reimbursement will ultimately determine the profit pool. “This is the crucial question,” she said. “You can have compelling clinical data — but without an economically viable reimbursement model, it becomes much harder to scale.” Today’s consumer-pay landscape highlights the uncertainty, with wide variation in list prices: Exact’s MCED test at $689, Grail’s at roughly $960, and Guardant’s at $1,495.
Meng pointed to the gap between underlying test economics and potential coverage levels as a central risk. “If reimbursement comes in below the fully loaded cost of running the test, the unit economics simply don’t work,” she said. “That forces the industry toward cost-down innovation, scale efficiencies, and more targeted clinical deployment.”
The Gabelli whitepaper similarly identifies reimbursement as the primary constraint to broad MCED adoption, noting that CMS evidence development is slow and requires large, long-duration studies. While the health-economic logic is directionally compelling — earlier-stage cancers are substantially less costly to treat than late-stage disease — translating population-level benefit into a sustainable per-test reimbursement rate remains the industry’s defining challenge.
Global Expansion and The Platform Evolution
Meng emphasized that the long-term opportunity in oncology diagnostics is not limited to screening, but the development of longitudinal platforms spanning early detection, minimal residual disease (MRD) monitoring, and treatment guidance — areas where companies such as Guardant, Natera, and others are actively expanding their capabilities.
“Screening is the entry point,” Meng said. “The long-term endgame is a longitudinal platform that supports cancer management across the continuum.” In her view, the strongest players will be those with multiple revenue-generating use cases across that continuum. Guardant, for example, combines screening (Shield) with MRD detection (Reveal) and tumor profiling (Guardant360), creating a more durable platform strategy than a single product alone.
“The strategic objective is to become an integrated oncology diagnostics platform,” Meng added. “A longitudinal model strengthens the health-economic argument: earlier detection paired with ongoing monitoring can reduce late-stage disease burden and overall cost of care — and that’s what ultimately drives reimbursement.” This aligns with the whitepaper’s long-term vision of shifting cancer toward a model of managed, longitudinal risk, analogous to cardiometabolic disease management.
The AI Accelerant and The Road Ahead
Meng argues that the MCED thesis is increasingly enabled by rapid progress in artificial intelligence. “AI is becoming a meaningful accelerant in diagnostics,” she said, pointing to its demonstrated impact in medical imaging as an early proof point. In her view, applying AI to blood-based assays can improve signal detection, drive more robust classification, and ultimately raise both sensitivity and predictive value — particularly in low-prevalence screening populations where performance requirements are unforgiving.
Looking ahead, Meng expects competition to intensify and the sector to consolidate. “I would not be surprised to see additional M&A in this space,” she said, noting that scaled strategic buyers may prefer acquiring platforms with clinical credibility and commercial momentum rather than building them from scratch. She highlighted Guardant as an example of a company that could fit that profile, given its breadth across screening, monitoring, and profiling.
For investors, Meng said the key milestones remain unchanged: Grail’s regulatory pathway and — equally important — the emergence of a sustainable reimbursement model. “The technology is advancing quickly, but reimbursement is what determines the profit pool,” she said.
Meng remains constructive on the long-term trajectory. “Blood-based screening has the potential to become part of standard-of-care over time,” she concluded. “The real question is timing — whether that adoption curve plays out over three years, five years, or closer to a decade.”
Her overall outlook is one of measured optimism: the unmet need is large, technical progress is real, and strategic interest is rising. In that context, the Abbott–Exact Sciences transaction is less an endpoint than a marker — signaling that large healthcare companies are increasingly willing to pay for commercial engines today and platform optionality tomorrow.
